MedTrace Logo

Clinical Trials

Showing trials with last updates posted in 2026.

NCT05136196 | RECRUITING | PHASE2
150 participants

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-04
Start Date:
2022-12-06
Completion:
2027-01-01
Conditions
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Locally Recurrent Head and Neck Squamous Cell Carcinoma
  • Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma
  • Locally Recurrent Laryngeal Squamous Cell Carcinoma
  • Locally Recurrent Oral Cavity Squamous Cell Carcinoma
  • Locally Recurrent Oropharyngeal Squamous Cell Carcinoma
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Metastatic Hypopharyngeal Squamous Cell Carcinoma
  • Metastatic Laryngeal Squamous Cell Carcinoma
  • Metastatic Melanoma
  • Metastatic Oral Cavity Squamous Cell Carcinoma
  • Metastatic Oropharyngeal Squamous Cell Carcinoma
  • Recurrent Melanoma
  • Stage III Hypopharyngeal Carcinoma AJCC v8
  • Stage III Laryngeal Cancer AJCC v8
  • Stage III Lip and Oral Cavity Cancer AJCC v8
  • Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage IV Hypopharyngeal Carcinoma AJCC v8
  • Stage IV Laryngeal Cancer AJCC v8
  • Stage IV Lip and Oral Cavity Cancer AJCC v8
  • Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Unresectable Melanoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
NCT05112601 | RECRUITING | PHASE2
81 participants

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-04
Start Date:
2022-06-02
Completion:
2032-07-30
Conditions
  • Endometrial Adenocarcinoma
  • Endometrial Clear Cell Adenocarcinoma
  • Endometrial Dedifferentiated Carcinoma
  • Endometrial Endometrioid Adenocarcinoma
  • Endometrial Mixed Cell Adenocarcinoma
  • Endometrial Mucinous Adenocarcinoma
  • Endometrial Undifferentiated Carcinoma
  • Endometrioid Adenocarcinoma
  • Recurrent Endometrial Carcinoma
Interventions
  • PROCEDURE
  • BIOLOGICAL
No Results Yet
NCT04991870 | RECRUITING | PHASE1
25 participants

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-04
Start Date:
2023-04-28
Completion:
2027-01-31
Conditions
  • Recurrent Gliosarcoma
  • Recurrent Supratentorial Glioblastoma
  • Supratentorial Gliosarcoma
Interventions
  • BIOLOGICAL
  • PROCEDURE
No Results Yet
NCT04947865 | COMPLETED | NA
54 participants

Reflex Excitability in Post-stroke Stiff-Knee Gait

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-04
Start Date:
2021-06-11
Completion:
2025-06-11
Conditions
  • Stroke
  • Chronic Stroke
  • Gait, Hemiplegic
  • Gait, Spastic
  • Gait Disorder, Sensorimotor
  • Gait Disorders, Neurologic
  • Walking, Difficulty
Interventions
  • OTHER
  • DEVICE
No Results Yet
NCT04858334 | RECRUITING | PHASE2
152 participants

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-04
Start Date:
2021-06-22
Completion:
2027-10-31
Conditions
  • Pancreatic Acinar Cell Carcinoma
  • Pancreatic Adenosquamous Carcinoma
  • Pancreatic Squamous Cell Carcinoma
  • Resectable Pancreatic Acinar Cell Carcinoma
  • Resectable Pancreatic Adenocarcinoma
  • Resectable Pancreatic Adenosquamous Carcinoma
  • Resectable Pancreatic Carcinoma
Interventions
  • PROCEDURE
  • DRUG
No Results Yet
NCT04704661 | ACTIVE_NOT_RECRUITING | PHASE1
51 participants

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Study Type:
INTERVENTIONAL
Last Updated:
2026-09-04
Start Date:
2021-08-09
Completion:
2027-03-31
Conditions
  • Advanced Breast Carcinoma
  • Advanced Colon Carcinoma
  • Advanced Colorectal Carcinoma
  • Advanced Endometrial Carcinoma
  • Advanced Gastric Carcinoma
  • Advanced Gastroesophageal Junction Adenocarcinoma
  • Advanced Malignant Solid Neoplasm
  • Advanced Salivary Gland Carcinoma
  • Anatomic Stage III Breast Cancer AJCC v8
  • Anatomic Stage IV Breast Cancer AJCC v8
  • Clinical Stage III Gastric Cancer AJCC v8
  • Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
  • Clinical Stage IV Gastric Cancer AJCC v8
  • Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
  • HER2-Positive Breast Carcinoma
  • Malignant Hepatobiliary Neoplasm
  • Metastatic Breast Carcinoma
  • Metastatic Colon Carcinoma
  • Metastatic Colorectal Carcinoma
  • Metastatic Endometrial Carcinoma
  • Metastatic Gastric Carcinoma
  • Metastatic Gastroesophageal Junction Adenocarcinoma
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Salivary Gland Carcinoma
  • Stage III Colon Cancer AJCC v8
  • Stage III Colorectal Cancer AJCC v8
  • Stage III Major Salivary Gland Cancer AJCC v8
  • Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
  • Stage IV Colon Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8
  • Stage IV Major Salivary Gland Cancer AJCC v8
  • Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
  • Unresectable Breast Carcinoma
  • Unresectable Colon Carcinoma
  • Unresectable Colorectal Carcinoma
  • Unresectable Endometrial Carcinoma
  • Unresectable Gastric Carcinoma
  • Unresectable Gastroesophageal Junction Adenocarcinoma
  • Unresectable Malignant Solid Neoplasm
  • Unresectable Salivary Gland Carcinoma
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page